Novel catheter treatment of valve disease

我们正在继续开发经导管二尖瓣环扎成形术，这是一种通过利用自然的(冠状静脉)和非自然的(心肌间隔内)轨迹来建立二尖瓣环周张力的新技术。我们已经在猪的缺血性心肌病模型中建立了环扎环成形术减少继发性(“功能性”)二尖瓣返流的原则证据。在我们改进设备的同时，我们正在努力向小企业发放新的合同，以资助将这项新技术合作转化为患者。 我们构思了一种治疗三尖瓣返流的全新方法，称为经耳心包内三尖瓣成形术(TRAIPTA)。我们已经在一个新的动物模型上证明了TRAIPTA在减少功能性三尖瓣反流方面的成功。我们最近与一家大型导管公司签订了一项合作研究和开发协议，以开发这项用于患者测试的技术。 我们开发了一种新技术，通过从下腔静脉进入腹主动脉，将大型植入物引入主动脉，用于经导管主动脉瓣置换术和相关手术。这挑战了长期以来的范式，即在非手术过程中，主动脉壁必须保持不受侵犯。这项技术已经在30多名患者中被证明是挽救生命的。我们正在对该技术进行多中心评估，同时开发专门设计的关闭接入端口的设备。这项技术在许多先天性心脏病的治疗和允许新的非手术进入心脏方面有应用。 我们正在开发一种无需手术即可通过胸壁进入心脏的创新方法。 我们正在与一家小企业合作，开发一种无需手术的部分二尖瓣置换术，使用一项新的外部发明来取代二尖瓣后瓣瓣，以治疗二尖瓣关闭不全，无论是功能性的还是退行性的。

We are continuing development of transcatheter mitral cerclage annuloplasty, a novel technique which establishes circumferential tension around the mitral valve annulus by exploiting both natural (coronary venous) and un-natural (intramyocardial septal) trajectories. We have established proof-of-principal in a porcine model of ischemic cardiomyopathy that cerclage annuloplasty reduces secondary ("functional") mitral valve regurgitation. While we refine devices, we are working to issue new contracts to small businesses to to fund collaborative translation of this novel technique into patients. We have conceived a wholly new approach to treat tricuspid valve regurgitation called transauricular intrapericardial tricuspid annuloplasty (TRAIPTA). We have demonstrated the success of TRAIPTA to reduce functional tricuspid regurgitation in a new animal model. We recently entered into a Collaborative Research and Development Agreement with a large catheter company to develop this technique for testing in patients. We have developed a new technique to introduce large implants into the aorta for transcatheter aortic valve replacement and related procedures, by crossing from the inferior vena cava into the abdominal aorta. This challenges the long-held paradigm that the aortic wall must remain inviolate during non-surgical procedures. The technique has proven lifesaving in over three dozen patients. We are sponsoring a multicenter evaluation of the technique while we develop purpose-built devices to close the access port. This technology has applications in the treatment of numerous congenital heart diseases and in allowing novel non-surgical access to the heart. We are developing an innovative approach to access the heart through the chest wall without surgery. We are working collaboratively with a small business to develop a partial mitral valve replacement without surgery, using a novel outside invention to replace the posterior mitral valve leaflet to treat mitral valve regurgitation whether functional or degenerative.